Clinical Trial Update: Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure. [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of once- and twice-daily doses of MCC-135 in subjects with congestive heart failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• MCC-135

Snippet

Sponsor: Takeda | Conditions: Congestive Heart Failure | Phase 2 | Status: COMPLETED